Will Herrington is a clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He jointly leads the Renal Studies Group which he joined in 2010 as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). He is Chief Investigator of the EMPA-KIDNEY trial which tested the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes. The trial has now entered a post-trial observational follow-up phase and is developing health economic analyses. He is on a number of clinical practice guideline working groups, and co-chairs the UK Kidney Association guideline group responsible for recommendations on the use of SGLT-2 inhibitors in adults with kidney disease. He is also interested in renal epidemiology, trial methodology and has chaired the UK Renal Trials Network since 2020.